@Article{,
AUTHOR = {Roseanne Ferreira, Emad Alwashmi, Samuel Otis-Chapados, Naeem Bhojani, Kevin C. Zorn, Bilal Chughtai, Dean S. Elterman},
TITLE = {Outcomes of sacral neuromodulation in male patients with overactive bladder, chronic pelvic pain, and fecal incontinence},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {31},
YEAR = {2024},
NUMBER = {4},
PAGES = {11943--11949},
URL = {http://www.techscience.com/CJU/v31n4/59575},
ISSN = {1488-5581},
ABSTRACT = {<b>Introduction:</b> Despite the growing body of literature
on sacral neuromodulation (SNM) outcomes, research
focusing on male patients remains limited and often
represented by small cohorts nested within a larger study
of mostly women. Herein, we evaluated the outcomes
of SNM in a male-only cohort with overactive bladder
(OAB), fecal incontinence (FI), chronic bladder pain, and
neurogenic lower urinary tract dysfunction (NLUTD).<br/>
<b>Materials and methods:</b> This retrospective cohort study
included 64 male patients who underwent SNM insertion
between 2013 and 2021 at a high-volume tertiary center.
Indications for SNM therapy included OAB, FI, chronic
pelvic pain, and NLUTD. Descriptive statistics, Fisher’s
and t-test were used in analysis.<br/>
<b>Results:</b> The mean age was 57.7 ± 13.4 years, and the
most frequent reason for SNM insertion was idiopathic
OAB (72%), FI (16%), pelvic pain (11%), and NLUTD
(11%). A majority (84%) of men received treatment
prior to SNM insertion. 84% reported satisfaction and
92% symptom improvement within the first year, and
these improvements persisted beyond 1 year in 73% of
patients. Mean follow up was 52.7 ± 21.0 months. The
complication rate was 23%, and the need for adjunct
treatments was significantly reduced (73% to 27%, p <
0.001). Treatment outcomes did not differ significantly
between various indications for SNM therapy or the
presence of benign prostatic hyperplasia (BPH).<br/>
<b>Conclusion:</b> SNM is an effective and safe procedure for male
patients with neurogenic and non-neurogenic OAB, pelvic
pain, and FI. Over 70% of patients experienced symptomatic
improvement and remained satisfied in the mid to long term
follow up. BPH does not seem to hinder treatment outcomes.},
DOI = {}
}